Ceftriaxone controlled release - scPharmaceuticals/Sensile Medical

Drug Profile

Ceftriaxone controlled release - scPharmaceuticals/Sensile Medical

Alternative Names: Cephalosporin antibiotic micropump patch - scPharmaceuticals

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator scPharmaceuticals
  • Class Antibacterials; Cephalosporins; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Bacterial infections

Most Recent Events

  • 26 Oct 2016 Pharmacokinetics data from a phase II/III trial in Bacterial infections (In volunteers) released by scPharmaceuticals (SC)
  • 02 Mar 2016 Ceftriaxone controlled release meets primary endpoints in its phase II/III trial inn Bacterial infections
  • 13 Nov 2015 scPharmaceuticals announces intention to submit NDA to the US FDA in 2H 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top